The entries of “Technologies made in Vienna” are displayed in the project language.
Technologies from Vienna
APEIRON Biologics AG
Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism, neoplasmsAPEIRON is a privately-held European biotech company based in Vienna, Austria, focused on the discovery and development of novel cancer immunotherapies.
APEIRON received EU marketing approval for APN311 (Dinutuximab beta, Qarziba®) in May 2017 for the treatment of pediatric neuroblastoma patients and out-licensed global, exclusive rights to this product to EUSA Pharma Ltd.
APEIRON now leverages its proprietary master checkpoint blockade mechanism to enable the human body’s natural defense mechanisms to fight tumors.
APEIRON’s lead clinical program APN401 is a first-in-class autologous cellular therapy to enhance immune reactivity via an intracellular immune master checkpoint, Cbl-b.
APEIRON’s key projects and technologies are bolstered by a strong patent portfolio with broad territorial coverage. APEIRON’s development expertise is validated through partnerships with leading global pharmaceutical companies and academic institutions.
Kontakt Wirtschaftsagentur Wien
Information and networking are co-funded by the European Fund for regional development as part of the „IC3 Innovation by Co-Operation, Co-Creation and Community Building“ project. Additional information on the IWB/EFRE funding programme